A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

This study tests sacituzumab tirumotecan (MK-2870), an antibody-drug combination, as a treatment delivered directly into the bladder (intravesical) for people with recurrent low-grade, non-muscle-invasive bladder cancer (cancer confined to the inner lining of the bladder). **You may be eligible if...** - You have been diagnosed with recurrent low-grade bladder cancer (Ta stage) that remains in the bladder lining - Your tumor is visible on a recent bladder scope (within the past 12 weeks) - You have had multiple tumors, early recurrence, a large solitary tumor (>3 cm), or previous bladder treatments that did not work - You are in reasonable health (ECOG 0–2) **You may NOT be eligible if...** - You have a newly diagnosed (first-ever) low-grade bladder cancer - You have ever had high-grade bladder cancer or cancer that has invaded the muscle wall - You have conditions preventing normal urination or holding urine - You have active inflammatory bowel disease or uncontrolled heart or brain vascular disease - You have severe dry eye syndrome or chronic corneal disease Talk to your doctor to see if this trial is right for you.